PUBLISHER: Grand View Research | PRODUCT CODE: 1301156
PUBLISHER: Grand View Research | PRODUCT CODE: 1301156
The global healthcare contract manufacturing market size is expected to reach USD 347.5 billion by 2030, expanding at a CAGR of 9.5% during the forecast period, according to a new report by Grand View Research, Inc. The changing regulatory landscape coupled with rising offshoring to emerging countries is anticipated to propel the healthcare contract manufacturing market growth over the forecast period. For instance, in June 2023, FUJIFILM Diosynth Biotechnologies announced to have a commercial office in Tokyo, offering contract development and manufacturing services for advanced therapies and biologics to Asian pharmaceutical and biotechnology companies.
Due to the emergence of infections, such as COVD-19 many organizations are attempting to accelerate production to meet the growing demand. Thus, these companies are appointing healthcare CMOs to speed up their production processes, as well as reduce their overall costs to meet the increasing demand for medical products. The worldwide effort to develop a vaccine and therapeutic agent against COVID-19 has created the greatest opportunity for many large as well as small CMOs as the pharmaceutical companies are manufacturing vaccine doses on large scale. Hence, the pandemic had a positive impact on this industry.
Increasing demand for advanced products is another factor driving the industry scale. Original Equipment Manufacturers (OEMs) are outsourcing the manufacturing activities of medical devices to third parties, mainly in developing countries to gain economic benefits. Furthermore, these regions are witnessing rising cases of chronic conditions such as heart disorders, thereby positively affecting the market growth. Changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost containment measures by OEMs. For instance, to prevent reimbursement issues from impacting financing goals, device manufacturers are developing a well-planned reimbursement strategy in parallel with their regulatory and clinical strategies in the early phases of product development.